Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Complement C1 inhibitor protein - CSL Behring

Drug Profile

Complement C1 inhibitor protein - CSL Behring

Alternative Names: Berinert; Berinert HS; Berinert P; C1 esterase inhibitor - CSL Behring; C1 esterase inhibitor concentrate; C1-INH - CSL Behring; CE 1145; Complement C1 inactivator - CSL Behring; CSL 830; CSL 842; Haegarda; Human C1 esterase inhibitor concentrate

Latest Information Update: 26 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSL Behring
  • Class Anti-ischaemics; Antianaemics; Complement C1 inactivator proteins; Eye disorder therapies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Complement C1s inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema; Angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Phase III Transplant rejection
  • Research Unspecified
  • Discontinued Reperfusion injury; Septic shock; Vascular disorders

Most Recent Events

  • 22 Feb 2019 Adverse events data from the phase III COMPACT trial in Hereditary angioedema (SC) presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2019)
  • 06 Nov 2018 Early research in Undefined indication in USA (unspecified route) (CSL Behring pipeline, November 2018)
  • 02 Mar 2018 Adverse events and efficacy data from the phase III COMPACT trial in Hereditary angioedema (SC) presented at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (AAAAI-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top